

## Reply to the Letter to the Editor

International Journal of Surgical Pathology  
2021, Vol. 29(2) 230  
© The Author(s) 2021  
Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: 10.1177/1066896920985731  
[journals.sagepub.com/home/ijsp](https://journals.sagepub.com/home/ijsp)



We thank the authors for their interest in our study. We concur with the site-specific recurrence rates of chondroblastoma as you point out. Indeed, with case series such as ours, the rate of recurrence may greatly depend on the clinical details of each tumor. We likewise concur with points 2 and 3 mentioned by you.

Finally, we concur that in most instances chondroblastoma is easily distinguished on morphologic grounds from

other diagnostic entities. It is on rare occasions, and usually with limited tumor sampling, that immunohistochemical or molecular studies are performed.

Respectfully,

Stefano Negri, MD  
Aaron W. James, MD, PhD  
Edward F. McCarthy, MD